PreHevbrio global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023
Continued execution across earlier-stage pipeline, including:
Initiation of Phase 2b study of VBI-1901 in.
PreHevbrio global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2
Expanded hepatitis B. -Today at 08:04 am- MarketScreener
PreHevbrio global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHevbrio continues to broaden – now available at several U.S. retail pharmacy chains. | May 15, 2023